Full Press Release Details
Rhythm Pharmaceuticals Presents Data from its Long term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Y.
RYTM
Rhythm Pharmaceuticals Presents Data from its Long term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Y
Key Takeaway: Rhythm Pharmaceuticals Presents Data from its Long term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Y